Filtered By:
Drug: Taxotere
This page shows you your search results in order of date. This is page number 18.
Order by Relevance | Date
Total 2210 results found since Jan 2013.
Drug-Drug interactions of docetaxel in patients with breast cancer based on insurance claims data
In conclusion, we suggest that coadministration of docetaxel and a predefined interacting drug are not associated with G-CSF prescription.PMID:37327237 | PMC:PMC10275435 | DOI:10.1371/journal.pone.0287382
Source: Cancer Control - June 16, 2023 Category: Cancer & Oncology Authors: Kwang-Hee Shin Young-Mi Ah Sang Hun Cha Hye Duck Choi Source Type: research
Targeting prostate cancer with docetaxel-loaded peptide 563-conjugated PEtOx-co-PEI < sub > 30% < /sub > -b-PCL polymeric micelle nanocarriers
Amino Acids. 2023 Jun 15. doi: 10.1007/s00726-023-03292-3. Online ahead of print.ABSTRACTProstate cancer is a global disease that negatively affects the quality of life. Although various strategies against prostate cancer have been developed, only a few achieved tumor-specific targeting. Therefore, a special emphasis has been placed on the treatment of cancer using nano-carrier-encapsulated chemotherapeutic agents conjugated with tumor-homing peptides. The targeting strategy coupling the drugs with nanotechnology helps to overcome the most common barriers, such as high toxicity and side effects. Prostate-specific membrane ...
Source: Amino Acids - June 15, 2023 Category: Biochemistry Authors: Ayca Ece Nezir Zeynep Busra Bolat Naile Ozturk Polen Kocak Ebru Zemheri Sevgi Gulyuz Umut Ugur Ozkose Ozgur Yilmaz Imran Vural Asuman Bozk ır Fikrettin Sahin Dilek Telci Source Type: research
Meta-Analysis of Atezolizumab vs Docetaxel in Non-Small Cell Lung Cancer Treatment Outcomes
CONCLUSION: Compared with docetaxel, atezolizumab can significantly prolong OS in patients with NSCLC and reduce the occurrence of TRAEs, but there is no advantage in PFS or ORR remission rate. Due to some limitations in case numbers and quality of included studies, multicenter, large sample, high-quality RCTs are still needed for further validation.PMID:37318886
Source: Alternative Therapies in Health and Medicine - June 15, 2023 Category: Complementary Medicine Authors: Yingya Fu Guojuan Xue Source Type: research
Targeting prostate cancer with docetaxel-loaded peptide 563-conjugated PEtOx-co-PEI < sub > 30% < /sub > -b-PCL polymeric micelle nanocarriers
Amino Acids. 2023 Jun 15. doi: 10.1007/s00726-023-03292-3. Online ahead of print.ABSTRACTProstate cancer is a global disease that negatively affects the quality of life. Although various strategies against prostate cancer have been developed, only a few achieved tumor-specific targeting. Therefore, a special emphasis has been placed on the treatment of cancer using nano-carrier-encapsulated chemotherapeutic agents conjugated with tumor-homing peptides. The targeting strategy coupling the drugs with nanotechnology helps to overcome the most common barriers, such as high toxicity and side effects. Prostate-specific membrane ...
Source: Amino Acids - June 15, 2023 Category: Biochemistry Authors: Ayca Ece Nezir Zeynep Busra Bolat Naile Ozturk Polen Kocak Ebru Zemheri Sevgi Gulyuz Umut Ugur Ozkose Ozgur Yilmaz Imran Vural Asuman Bozk ır Fikrettin Sahin Dilek Telci Source Type: research
Meta-Analysis of Atezolizumab vs Docetaxel in Non-Small Cell Lung Cancer Treatment Outcomes
CONCLUSION: Compared with docetaxel, atezolizumab can significantly prolong OS in patients with NSCLC and reduce the occurrence of TRAEs, but there is no advantage in PFS or ORR remission rate. Due to some limitations in case numbers and quality of included studies, multicenter, large sample, high-quality RCTs are still needed for further validation.PMID:37318886
Source: Alternative Therapies in Health and Medicine - June 15, 2023 Category: Complementary Medicine Authors: Yingya Fu Guojuan Xue Source Type: research
Identification of cardiotoxicity related to non-small cell lung cancer (NSCLC) treatments: A systematic review
Conclusion: The findings of this systematic review have provided a better understanding of the possible association between cardiotoxicities and anticancer drugs for NSCLC. Whilst variation is observed across different drug classes, the lack of information available on cardiac monitoring can result in underestimation of this association.Systematic Review Registration:https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020191760, identifier PROSPERO CRD42020191760.
Source: Frontiers in Pharmacology - June 13, 2023 Category: Drugs & Pharmacology Source Type: research
Survival Impact of Second-Line Immune Checkpoint Inhibitors in Older Patients With Advanced Squamous-Cell NSCLC: Post Hoc Analysis of the CAPITAL Study
CONCLUSIONS: We found that second-line ICI treatment seemed to have a little impact on OS.PMID:37304652 | PMC:PMC10250914 | DOI:10.1016/j.jtocrr.2023.100514
Source: Clinical Lung Cancer - June 12, 2023 Category: Cancer & Oncology Authors: Yoshihito Kogure Akiko Kada Hiroya Hashimoto Shinji Atagi Yuichi Takiguchi Hideo Saka Noriyuki Ebi Akira Inoue Takayasu Kurata Yuka Fujita Yoichi Nishii Hidetoshi Itani Takeo Endo Akiko M Saito Takuo Shibayama Nobuyuki Yamamoto Akihiko Gemma Source Type: research
The oncogenic protein kinase/ATPase RIOK1 is up-regulated via the MYC/E2F transcription factor axis in prostate cancer
In this study, we examined the expression, regulation and therapeutic potential of RIOK1 in PCa. RIOK1 mRNA and protein expression were elevated in PCa tissue samples and correlated with proliferative and protein homeostasis related pathways. RIOK1 was identified as a downstream target gene of the MYC/E2F transcription factors. RIOK1 knock-down and over-expression of the dominant-negative RIOK1-D324A mutant significantly reduced proliferation of PCa cells. Biochemical inhibition of RIOK1 with toyocamycin led to strong anti-proliferative effects in AR-negative and -positive PCa cell lines with EC50 values from 3.5 to 8.8 nM...
Source: The American Journal of Pathology - June 10, 2023 Category: Pathology Authors: Florian Handle Martin Puhr Martina Gruber Chiara Andolfi Georg Sch äfer Helmut Klocker Johannes Haybaeck Peter De Wulf Zoran Culig Source Type: research
